Wedbush Reiterates Outperform on Xencor, Maintains $26 Price Target
Xencor Inc XNCR
$20.21
▼ -5.96%
($-1.28)
📅 Earnings This Week
Open
$21.50
Prev Close
$21.49
Day Range
$19.77 – $21.57
52W Range
$6.92 – $21.76
Market Cap
$1.59B
Beta
0.84
EPS (TTM)
$-2.30
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-12-03 |
| Shares Out. | 74,140,000 |
| Website | xencor.com/ ↗ |
| Phone | 13026587581 |
| Employees | 260 |
| Revenue | $4.5M |
| Gross Profit | $4.5M |
| Net Income | -$128.9M |
| Free Cash Flow | -$188.8M |
| Total Assets | $736.8M |
| Total Liabilities | $221.2M |
| Equity | $515.6M |
About Xencor Inc
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
Xencor Inc is a publicly traded company under the ticker symbol XNCR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)